News | October 30, 2023
Tanaka develops first high entropy precious metals alloy powder
With the establishment of five different precious metals alloy powder production methods
With the establishment of five different precious metals alloy powder production methods
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Dr Jitendra Singh launches API Chapter of AFMC, Pune; inaugurates the first annual conference of API-AFMS Continuing Medical Education (CME) on “Emerging trends in the practice of Medicine”
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
